Arrowhead Pharmaceuticals, a leading genetic medicine company, will establish operations in Verona, Wisconsin. The $220 million project is expected to create 230 jobs.
The new campus, which will consist of two buildings, will complement the company’s existing 111,000-square-foot research and development facility in Madison.
The first building is an approximately 125,000-square-foot laboratory and office facility that will support process development and analytical activities. The second is an approximately 160,000-square-foot GMP drug manufacturing facility, which company leaders say will be critical to Arrowhead’s global operations....
Ken Notes: Wow 80K per employee that is a lot of money but the amount is under my 10% threshold based on 220 Million in valuation assuming they get that valuation in writing. I hope whoever is drafting the development agreement got an A in contracts class.
Also from the fine print, "The company was forced to scrap its entire clinical pipeline in 2016 following deaths in a non-human primate toxicology study. The company faced a similar issue in July of 2021 when it paused the Phase I/II trial of RNAi cystic fibrosis drug ARO-ENaC after a study in rats showed lung inflammation signals."
- - Volume: 10 - WEEK: 20 Date: 5/12/2022 9:20:59 AM -